Legend Biotech (LEGN) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $3.22B
- As of Nov 13, 2026
- P/E
- -10.84x
- Latest fiscal year
- P/B
- 3.21x
- Latest reported equity
- P/S
- 3.13x
- Latest fiscal year
- ROE
- -29.6%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $3.22B
- As of Nov 13, 2026
- P/E
- -10.84x
- Latest fiscal year
- P/B
- 3.21x
- Latest reported equity
- P/S
- 3.13x
- Latest fiscal year
- ROE
- -29.6%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
-10.84x
Net loss — not comparable
P/B
3.21x
P/S
3.13x
Earnings and dividend metrics▾
Earnings
EPS
-$0.80
Earnings per share
BPS
$2.71
Book value per share
ROE
-29.6%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.80 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $2.71 of net assets.
- ROE — shareholder equity shrank by 29.6% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsOct–Dec 2025(FY2025 Q4)
Revenue in the latest quarter: $307M.
Key reported figures come first. Select one to see the same quarter across three years.
The fourth-quarter figure is the annual total minus the first three quarters.
Revenue · same quarter, three years
No year-ago figure was found for this quarter.
Annual total minus the first three quarters (the filing does not report the fourth quarter on its own).
—
FY23 Q4
—
FY24 Q4
$307M
Oct–Dec '25
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Oct–Dec 2025 are from the 20-F submitted to SEC EDGAR on Mar 10, 2026.
- Revenue is the annual total minus the first three quarters; the filing does not report the fourth quarter on its own.
- Revenue has no year-ago figure on record, so no comparison is made.
- Net income is the annual total minus the first three quarters; the filing does not report the fourth quarter on its own.
- Net income has no year-ago figure on record, so no comparison is made.
Filed Mar 10, 2026 · 20-F · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Sanders Corazon (Corsee) D.Director · Sep 29, 2026Open-market sale27,370 shares · $259KAvg. price $9.4652,731 shares held after
- Casey Patrick JohnDirector · Sep 24, 2026Grant or award20,986 shares · $0Avg. price $069,590 shares held after
- Mao LiDirector · Sep 24, 2026Grant or award20,986 shares · $0Avg. price $065,316 shares held after
- Salovey PeterDirector · Sep 24, 2026Grant or award28,330 shares · $0Avg. price $055,096 shares held after
- Heyman Tomas J.Director · Sep 24, 2026Grant or award20,986 shares · $0Avg. price $053,720 shares held after
- Ji Darren XiaohuiDirector · Sep 24, 2026Grant or award28,330 shares · $0Avg. price $092,103 shares held after
- Sanders Corazon (Corsee) D.Director · Sep 24, 2026Grant or award20,986 shares · $0Avg. price $080,101 shares held after
- Santos Carlos EChief Financial Officer · Sep 21, 2026Open-market sale5,430 shares · $50KAvg. price $9.1414,246 shares held after
- Santos Carlos EChief Financial Officer · Sep 21, 2026Grant or award19,676 shares · $0Avg. price $019,676 shares held after
- Zhang IngridChief Executive Officer · Sep 15, 2026Grant or award1,131,860 shares · $0Avg. price $01,131,860 shares held after
- BASH ALANInterim CEO · Aug 14, 2026Grant or award4,908 shares · $0Avg. price $035,142 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Legend Biotech (LEGN) stock information
NASDAQ
Legend Biotech (LEGN) is listed on NASDAQ. Its market capitalization is about $3.2B. On trailing-twelve-month earnings the P/E ratio is -10.84, and the P/B ratio is 3.21. Return on equity is -29.6%. These figures are computed in-house from official filings and are reference information only.
Legend Biotech — frequently asked questions
- What is the P/E ratio of Legend Biotech (LEGN)?
- On a trailing-twelve-month basis, LEGN trades at a P/E ratio of -10.84. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Legend Biotech?
- LEGN has a market capitalization of about $3.2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.